For decades, treating obstructive sleep apnea has followed a familiar script: diagnose the condition with a sleep study, prescribe a CPAP machine, and hope the patient can tolerate it. A new review published in Respirology argues that this one-size-fits-all approach is giving way to something more targeted — and potentially more effective.
The review, led by Walter T. McNicholas of University College Dublin, examines the growing field of OSA "endotyping," the practice of identifying the specific biological mechanism driving each patient's airway collapse. The central finding: not everyone with sleep apnea has the same underlying problem, and treatments can now be matched accordingly.
Four Reasons Airways Collapse
Researchers have identified four distinct endotypes — biological subtypes — that contribute to obstructive sleep apnea, sometimes in combination:
-
Anatomical narrowing: The most common factor. Some people have physically narrower or more collapsible airways due to jaw structure, tongue size, or soft tissue volume. This is the classic cause of sleep apnea and the one CPAP addresses most directly.
-
Poor upper airway muscle responsiveness: During sleep, muscles in the throat normally compensate for gravity and relaxation by stiffening when they sense the airway closing. In some patients, this reflex is weak or absent, allowing the airway to collapse despite adequate anatomy.
-
High loop gain: This refers to an oversensitive breathing control system. The brain overreacts to small changes in blood oxygen and carbon dioxide levels, creating a cycle where breathing oscillates between too much and too little — triggering repeated airway closures.
-
Low arousal threshold: Some patients wake up too easily in response to minor breathing disturbances. While this sounds protective, it actually prevents the brain from activating the compensatory mechanisms that would reopen the airway, leading to fragmented sleep and repeated obstruction events.
Matching Treatments to Mechanisms
The practical significance of endotyping is that different mechanisms respond to different therapies. The review maps out how treatments align with specific endotypes:
For anatomical narrowing, the traditional approaches remain most effective: CPAP and bilevel devices directly splint the airway open, while oral appliances advance the jaw to increase airway space. Weight loss reduces tissue volume around the airway. Surgical options, including hypoglossal nerve stimulation implants, can also help.
For poor muscle responsiveness, neurostimulation therapies that activate the hypoglossal nerve during sleep show promise. Pharmacological approaches targeting upper airway muscle tone — including combination drugs like AD109, which uses a norepinephrine reuptake inhibitor paired with an antimuscarinic agent — are advancing through clinical trials.
For high loop gain, medications that stabilize the brain's ventilatory control system, such as acetazolamide and oxygen supplementation, can dampen the overreactive breathing response. This endotype is particularly relevant in patients whose sleep apnea worsens at altitude or who have significant central apnea mixed in with obstructive events.
For low arousal threshold, sedative medications that raise the threshold for waking — allowing the brain to activate natural airway-protective reflexes rather than jolting awake — could paradoxically improve breathing during sleep. This approach requires careful management, since overly sedating a patient with severe airway collapse could be dangerous.
Identifying Endotypes in Practice
A key challenge has been translating endotyping from research laboratories into clinical practice. Traditional methods required complex physiological measurements during sleep studies, making them impractical for routine use.
The review notes that recent work has produced simplified tools that can estimate endotypic traits from standard polysomnography data — the same overnight sleep studies already used to diagnose sleep apnea. This means clinicians may soon be able to identify a patient's dominant endotype without additional testing.
CPAP Isn't Going Anywhere — But It Won't Be Alone
The authors are clear that CPAP will remain the primary treatment for moderate and severe sleep apnea for the foreseeable future. No alternative therapy yet matches its effectiveness for patients with significant airway collapse.
But for the estimated 50% of patients who abandon CPAP within the first year, endotype-guided alternatives could fill a critical gap. And for patients with mild to moderate sleep apnea — where the cost-benefit calculation of wearing a mask every night is harder to justify — targeted therapies may eventually become first-line options.
The question is shifting from "Does this patient have sleep apnea?" to "Why does this patient have sleep apnea?" The answer could determine which treatment actually works for them.
What This Means for Patients
The shift toward precision sleep medicine is still in its early stages. Most patients today will not receive endotype testing as part of a standard sleep apnea workup. But the direction is clear, and several developments are accelerating the timeline:
- Oral medications targeting specific endotypes are nearing FDA approval
- Devices like Kricket that adapt pressure delivery are already FDA-cleared
- Sulthiame, an existing epilepsy drug, showed a nearly 50% reduction in breathing interruptions in a recent clinical trial
- Hypoglossal nerve stimulation is expanding to new device platforms
For patients struggling with CPAP or wondering whether a lighter intervention might work, the message from this research is cautiously optimistic: science is getting closer to understanding not just that your airway collapses, but why — and that distinction could eventually make all the difference.
